



Date: 14.11.2023

To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India
Limited (NSE)
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai – 400051
NSE SYMBOL: MKPL

Sub: Outcome of the Board Meeting - Unaudited Financial Results for the quarter and half year ended September 30, 2023

Dear Sir/Madam,

Pursuant to the Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today i.e. on Tuesday, November 14, 2023, *inter alia*, considered and approved the Un-Audited Financial Results for the quarter and half year ended September 30, 2023 along with the Limited Review Report thereon by the Statutory Auditors of the Company.

A copy of the Un-Audited Financial Results along with Limited Review Report of the Auditors is attached herewith as Annexures.

Kindly note that the meeting of the Board of Directors commenced at 05:00 p.m. and concluded at 5:55 p.m.

You are requested to take the same on your record.

Thanking You,

**Yours Faithfully,
FOR M K PROTEINS LIMITED**

**Parmod Kumar
Managing Director
DIN: 00126965**

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01013



K R A & C O.
Chartered Accountants

☎ 011 - 47082855
Fax: 011 - 47082855

H -1/208, Garg Tower, Netaji Subhash Place, Pitampura, New Delhi -110034

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of M K Proteins Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("the Statement") of **M K Proteins Limited** ("the Company") for the quarter and half year ended September 30, 2023 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulation').
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34") prescribed under section 133 of the Companies Act 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India (Listing and Disclosure Requirements) Regulations, 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KRA & Co.

Chartered Accountants

(Firm Registration No.020266N)



Rajat Goyal

Partner

Membership No.: 503150

UDIN: 23503150BGWHWD5107

Place: New Delhi

Date: November 14, 2023.

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Gamala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2023

(Rs. In Lakh)

	QUARTER ENDED		HALF YEAR ENDED		YEAR ENDED
	30-09-2023 (UNAUDITED)	30-06-2023 (UNAUDITED)	30-09-2023 (UNAUDITED)	30-09-2022 (UNAUDITED)	31-03-2023 (AUDITED)
1. Revenue					
a) Revenue from Operation (Net)	1364.05	7619.51	8983.56	13950.53	31486.00
b) Other Income	2.98	0.00	2.98	2.06	5.69
Sub-Total "1"	1367.03	7619.51	8986.54	13952.59	31491.69
2. Expenditure					
a) Cost of Material Consumed	497.72	3192.89	3690.61	9630.80	25574.42
b) Purchase of Stock-in-Trade	880.22	1457.11	2337.33	2723.74	4912.19
c) Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade	(221.34)	2107.70	1886.36	421.19	(1967.95)
d) Employees Benefits Expenses	67.35	68.72	136.07	92.73	176.29
e) Manufacturing, Operating and Other Expenses	76.25	393.23	469.48	477.23	1087.19
f) Finance Costs	3.64	52.37	56.01	69.43	173.37
g) Depreciation and Amortization Expenses	11.74	11.61	23.35	37.97	75.77
Sub-Total "2"	1315.58	7283.63	8599.21	13453.09	30031.28
3 Profit/(Loss) before Exceptional, Extraordinary items and Tax [1 - 2]	51.45	335.88	387.33	499.50	1460.41
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) before Extraordinary items and Tax [3 - 4]	51.45	335.88	387.33	499.50	1460.41
6 Extraordinary Items	0.00	0.00	0.00	0.00	0.00
7 Profit/(Loss) before Tax [5 - 6]	51.45	335.88	387.33	499.50	1460.41
8 Tax Expenses					
a) Provision for Current Tax	11.63	86.37	98.00	127.99	399.52
b) Provision for Deferred Tax Liability/(Adjustment)	(1.38)	0.46	(0.92)	(1.59)	(3.71)
c) Prior Year Taxes	0.00	0.00	0.00	0.00	0.00
Sub-Total "8"	10.25	86.83	97.08	126.40	395.81
9 Profit/(Loss) for the Period from continuing operations [7 - 8]	41.20	249.05	290.25	373.10	1064.60
10 Profit/(Loss) for the period from Discontinuing operations before tax	0.00	0.00	0.00	0.00	0.00
11 Tax expenses of Discontinuing operations	0.00	0.00	0.00	0.00	0.00
12 Profit/(Loss) from Discontinuing operations (After Tax) [10 - 11]	0.00	0.00	0.00	0.00	0.00
13 Profit/(Loss) for the period [9 + 12]	41.20	249.05	290.25	373.10	1064.60
14 Other Comprehensive Income net of taxes					
a) (i) Amount of items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
(ii) Income Tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
b) (i) Amount of items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
(ii) Income Tax relating to items that will be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
Sub- Total "14"	0.00	0.00	0.00	0.00	0.00
15 Total comprehensive Income for the Period [13 + 14]	41.20	249.05	290.25	373.10	1064.60
16 Earnings per share					
a) Earnings per Equity Share for continuing operations					
Basic earnings/(Loss) per share from continuing operations	0.33	1.99	2.32	8.95	8.51

	Diluted earning/(Loss) per share from continuing operations	0.33	1.99	2.32	8.95	8.51
b)	Earnings per Equity Share for discontinuing operations					
	Basic earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00
	Diluted earning/(Loss) per share from discontinuing operations	0.00	0.00	0.00	0.00	0.00
c)	Earnings per Equity Share					
	Basic earning/(Loss) per share from continuing and discontinuing operations	0.33	1.99	2.32	8.95	8.51
	Diluted earning/(Loss) per share from continuing and discontinuing operations	0.33	1.99	2.32	8.95	8.51
17	Details of Equity Share Capital					
	Paid-up Equity Share Capital	1251.24	1251.24	1251.24	417.08	1251.24
	Face value of Equity Share Capital	10	10	10	10	10
18	Other Equity (Reserves)	-	-	4066.19	3916.44	3775.94


Note:

1. The above-mentioned audited results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 14th November, 2023.
2. Previous year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
3. The above results have been reviewed by the Statutory Auditor as required under regulation 33 of SEBI (Listing Obligations and disclosures Requirements) Regulations, 2015.
4. The Company has adopted Indian Accounting Standard ("Ind As") with effect from 1st April 2023 and the financial results for the quarter ended 30th September, 2023 has been prepared as per the recognition and measurement principles of Ind As. As required under the SEBI (Listing Obligations and disclosures Requirements) Regulations, 2015 the comparative results for the corresponding half year in the previous year i.e. ended 30th September 2022 have been restated in accordance with the recognition and measurement principles of Ind AS. The management has exercised necessary due diligence and ensured that the financial results provided true and fair view of its affairs in accordance with the companies (Indian Accounting Standards) Rule 2015. These results have been disclosed in the format specified in Schedule III of the Companies Act, 2013 as prescribed by the Circular on "Revised Format for financial Results and Implementation of Ind AS by listed Entities dated 5th July 2016 issued by SEBI.
5. Disclosure of assets and liabilities as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September, 2023 is given as per Annexure "I" attached

Place: Ambala

Dated: 14-11-2023

For and on behalf of the board


(Parmod Kumar)
Managing Director
DIN: 00126965

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003
T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com
CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

ANNEXURE "I"


STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2023 IS GIVEN BELOW: -

	PARTICULARS	AS AT	AS AT
		30-09-2023	31-03-2023
		(UNAUDITED)	(AUDITED)
A	ASSETS		
1	Non-Current Assets		
	-Property, Plant and Equipment	212.94	235.96
	-Capital Work-in-Progress	0.00	0.00
	-Intangible assets	0.00	0.00
	Financial Assets		
	-Investments	0.00	0.00
	-Other financial assets	42.35	42.35
	Deferred Tax Assets (net)	34.65	33.73
	Other non-current assets	44.64	44.64
	Sub-Total "1" Non-Current Assets	334.58	356.68
2	Current Assets		
	-Inventories	3187.26	7120.49
	Financial Assets		
	-Investments	297.98	0.00
	-Trade Receivables	2896.22	1640.68
	-Cash and Cash Equivalents	10.92	6.25
	-Other Financial assets	0.00	0.00
	Current Tax Assets (Net)	0.00	0.00
	Other Current Assets	61.27	1125.86
	Sub-Total "2" Current Assets	6453.65	9893.28
	TOTAL ASSETS	6788.23	10249.96
B	EQUITY AND LIABILITIES		
1	Equity		
	-Equity Share Capital	1251.24	1251.24
	-Other Equity	4066.19	3775.94
	Sub-Total "1" Total of Equity	5317.43	5027.18
2	Liabilities		
	Non-Current Liabilities		
	Financial Liabilities		
	-Long Term Borrowings	0.00	254.18
	-Other financial liabilities	0.00	0.00
	Provisions	9.89	9.89
	Deferred Tax Liabilities (net)	0.00	0.00
	Other non-current liabilities	0.00	0.00
	Sub-Total Non-Current Liabilities	9.89	264.07
	Current Liabilities		
	Financial Liabilities		
	-Short Term Borrowings	730.13	4198.17
	-Trade Payables	592.29	480.24
	-Other Financial Liabilities	11.17	38.43
	Other Current Liabilities	91.65	85.76
	Provisions	0.00	0.00
	Current Tax Liabilities (Net)	35.67	156.11
	Sub-Total Current Liabilities	1460.91	4958.71
	TOTAL EQUITY AND LIABILITIES	6788.23	10249.96

Place: Ambala

Dated: 14-11-2023

For and on behalf of the board


 (Parmod Kumar)
 Managing Director
 DIN: 00126965

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnaala, Ambala City (Haryana), India - 134003
 T: 0171-2679358 | W: www.mkproteins.in | E: compliancembkproteins@gmail.com
 CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2023

	PARTICULARS	FOR THE HALF YEAR ENDED 30/09/2023 UNAUDITED	FOR THE YEAR ENDED 31/03/2023 AUDITED
A.	CASH FLOW FROM OPERATING ACTIVITIES		
	-Net Profit/(Loss) before tax	387.33	1460.41
	-Adjustment for:-		
	Depreciation and amortisation expenses	23.35	75.77
	Interest Expenses	56.01	173.37
	Provision of allowances for Bad and Doubtful debts (Excepted credit loss allowance)	0.00	0.00
	Provision for Retirement Gratuity Benefit to Employees	0.00	2.16
	Net Gain on Sale/Fair Valuation of Investment on FVTPL	(2.98)	(0.90)
	Interest Income	0.00	(1.16)
	Operating profit before working capital changes	463.71	1709.65
	Adjustment for (Increase)/Decrease in operating assets:		
	-Trade Receivables	(1255.55)	1280.22
	-Inventories	3933.23	(2143.68)
	-Other Non-Current Assets	0.00	(44.64)
	-Other Current Assets	1064.60	(939.55)
	Adjustment for Increase/(Decrease) in operating Liabilities:		
	-Trade Payables	112.05	(22.90)
	-Other Financial Current liabilities	(27.26)	20.00
	-Other Current Liabilities	5.89	27.21
	-Provisions	0.00	0.00
	Cash use in / generated from operation	4296.67	(113.69)
	-Direct taxes paid	(218.44)	(482.61)
	NET CASH FROM OPERATING ACTIVITIES	4078.23	(596.30)
B.	CASH FLOW FROM INVESTING ACTIVITIES		
	-Sale Proceed of fixed assets	0.00	0.00
	-Sale Proceeds for Investment in Mutual Funds	0.00	455.90
	-(Increase)/Decrease in Bank Balances not considered as Cash and Cash Equivalent	0.00	0.00
	-Purchase of Investment	(295.00)	(455.00)
	-Fixed Assets Purchases	(0.33)	(0.72)
	-Income Tax Refund Received	0.00	0.00
	-Interest Income	0.00	1.16
	NET CASH FROM INVESTING ACTIVITIES	(295.33)	1.34

C.	CASH FLOW FROM FINANCING ACTIVITIES		
	-Increase/(Decrease) in Short term Bank Borrowings	(3466.46)	784.33
	-Increase in Long Term Borrowings	0.00	0.00
	-Repayment of long term borrowings	(255.76)	(10.42)
	-Finance cost	(56.01)	(173.37)
	NET CASH FROM FINANCING ACTIVITIES	(3778.23)	600.54
	NET CASH FLOW DURING THE YEAR (A+B+C)	4.67	5.58
	Cash and Cash Equivalent at beginning of the period	6.25	0.67
	Cash and Cash Equivalent at end of the period	10.92	6.25

Place: Ambala

Dated: 14-11-2023

For and on behalf of the board


(Parmod Kumar)
Managing Director
DIN: 00126965